Maropitant for Ducks: Uses, Dosing & Side Effects

This information is for educational purposes only. Never give your pet any medication without your veterinarian's guidance. Dosing, frequency, and safety depend on your pet's specific health profile.

Maropitant is an anti-nausea and anti-vomiting medication that blocks neurokinin-1 (NK1) receptors and reduces the effects of substance P, a chemical involved in the vomiting pathway. In the United States, it is sold most commonly as Cerenia and is FDA-approved for dogs and cats, not ducks. That means use in ducks is off-label and should only happen under your vet's direction.

In birds, maropitant is used empirically when your vet is concerned about nausea, regurgitation, or vomiting-like signs as part of a larger illness workup. Ducks can become dehydrated and weak quickly when they stop eating, so anti-nausea support may be one piece of a broader treatment plan that also addresses fluids, warmth, nutrition, pain control, and the underlying disease.

Published avian data are still limited. A pharmacokinetic study in domestic chickens found that 1-2 mg/kg given subcutaneously produced measurable blood levels, with modeling suggesting dosing every 12-24 hours may be needed to maintain concentrations similar to those targeted in dogs. Because chickens are not ducks, and species differences matter, your vet may adjust the plan based on your duck's condition, age, hydration, liver function, and response to treatment.

Your vet may consider maropitant in ducks when there are signs consistent with nausea or upper gastrointestinal upset. That can include repeated head shaking after swallowing, regurgitation, reduced appetite, stress around feeding, or vomiting-like episodes. It may also be used when a duck is receiving other treatments or procedures that could trigger nausea.

Common real-world reasons your vet might discuss maropitant include crop or upper GI irritation, toxin exposure, systemic illness, post-anesthetic recovery, severe motion or handling stress, and supportive care during hospitalization. In some species, maropitant may also help with visceral discomfort, so your vet may use it as part of a multimodal plan rather than as a stand-alone drug.

It is important to remember that maropitant does not treat the cause of the problem. A duck with regurgitation or appetite loss may have infection, heavy metal exposure, obstruction, reproductive disease, liver disease, parasitism, or another urgent condition. If your duck is weak, breathing hard, unable to stand, or repeatedly bringing up fluid or food, see your vet promptly.

There is no FDA-approved duck dose for maropitant. In avian medicine, dosing is extrapolated from other species and from limited bird-specific studies. A commonly discussed avian starting range is 1-2 mg/kg, often by subcutaneous injection, with an interval of every 12-24 hours depending on the species, clinical goal, and your vet's judgment. In chickens, a pharmacokinetic study supported that 1-2 mg/kg SC may maintain target plasma concentrations for roughly that interval, but ducks may handle the drug differently.

Because maropitant is prescription-only and off-label in ducks, your vet should calculate the exact dose. Small errors matter in birds. The concentration of injectable Cerenia is 10 mg/mL, so even a tiny volume change can significantly alter the delivered dose in a lightweight duckling or small breed duck.

Your vet may lower the dose, extend the interval, or avoid the drug in ducks with liver disease, severe debilitation, or uncertain hydration status. Oral use is less standardized in ducks than injectable use. If your duck spits out medication, regurgitates after dosing, or seems more depressed afterward, contact your vet before giving another dose.

Most of the formal safety data for maropitant come from dogs and cats, so side effects in ducks are not as well defined. In companion animals, the most recognized issues are injection discomfort, drooling, reduced appetite, lethargy, diarrhea, and occasional swelling or soreness at the injection site. In birds, your vet will also watch for worsening weakness, reduced food interest, and changes in droppings after treatment.

Call your vet if your duck seems markedly sleepy, collapses, stops eating, develops diarrhea, shows injection-site swelling, or has ongoing regurgitation despite treatment. Those signs may reflect the medication, the underlying illness, or both. In a sick bird, it can be hard to separate one from the other, which is why follow-up matters.

Use extra caution in breeding birds or birds that may be laying fertile eggs. An in ovo chicken study found increased embryo death at higher maropitant exposures, so your vet may weigh risks carefully in reproductively active birds. If your duck is pregnant, actively laying for breeding, or part of a flock with food-production considerations, bring that up before treatment starts.

Maropitant is metabolized primarily by the liver, so your vet will be thoughtful when combining it with other medications that also rely heavily on hepatic metabolism. Formal interaction studies in ducks are lacking, but caution is reasonable when maropitant is used alongside sedatives, anesthetic drugs, antifungals, some antibiotics, and other medications that may affect liver function or cause sedation.

In dogs and cats, product information advises monitoring compatibility when maropitant is used with adjunctive therapy. For ducks, that means your vet may review the full medication list, including pain medications, dewormers, supplements, compounded drugs, and any over-the-counter products you may have given at home.

Tell your vet if your duck has known liver disease, toxin exposure, dehydration, or recent anesthesia, because those details can change whether maropitant is a good fit. Never combine maropitant with another medication because it "helped before" without checking first. The safest plan depends on the whole case, not the drug alone.